
Early this week I got to sit with Element Biosciences founders Molly He (CEO) and Michael Previte (CTO) in their comically big board room and we had a great in-depth conversation about their careers and building Element.
All up a fantastic discussion and in my humble đ opinion an entire MBA packed into one hour of easy listening!
1. How the hell did you two get here?
- Mollyâs personality: competitive sprinting, love of travel and risk-taking, proteomics obsession
- Mikeâs early work in cancer research, multi-drug resistance, and developing a deep interest in the complexity of biology
2. The Elemental Elements of Element
- How Molly, Mike, and Matt  met (Illumina, PacBio, Foresight Capital)
- Fundamental motivation: do âsmart scienceâÂ
- Early challenges in getting the chemistry to work in a moldy lab
3. Flashback: the PacBio and Illumina Years
- PacBioâs single-molecule real-time sequencing: the need to engineer polymerases for precise optical detection
- Illuminaâs ecosystem building and how crucial sample prep, workflows, and system-level thinking are for successÂ
4. Oof: Competing with Illumina
- The need for brand-building and overcoming customer risk aversion (âno one gets fired for buying IBMâ)
- Tactics like running customer samples internally to show quality and reliability
5. Differentiating Technology & Vision
- Elementâs approach to âsmart scienceâ rather than purely high-throughput sequencing data generation
- Building a sequencing system with the ability to capture broader multiomic information (protein engineering, optical methods)
- Emphasis on simultaneous/spontaneous multiomics readouts (DNA, RNA, proteins) from the same samples on the same machine
6. Market Dynamics and Customer Adoption
- Compatibility with Illumina workflows (sample prep, data output) to reduce switching costs
- The impact of new entrants (e.g., Ultima Genomics, Roche and potential market fragmentation around different core competencies
7. Looking Ahead: Multiomics & Precision Medicine
- The need for deeper, integrated biological assays to tackle chronic diseases such as diabetes
- Limitations of only knowing gene sequences without functional data (RNA expression, protein profiles, morphology)
- Long-term goal to move beyond being âjustâ a sequencer company and enable more holistic, comprehensive biology insights
8. Reflections on Entrepreneurship & Innovation
- âNaivetyâ (or âdelusionâ) as both a necessity and a driver of ambition for founders
- The balance between taking big risks and being prepared with strong science/engineering fundamentals
- Continued commitment to building a powerful platform that can adapt to future breakthroughs in life science research
More episodes from "The Geonomics Podcast"



Don't miss an episode of âThe Geonomics Podcastâ and subscribe to it in the GetPodcast app.








